<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="304">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 03, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04262921</url>
  </required_header>
  <id_info>
    <org_study_id>C20-05</org_study_id>
    <secondary_id>2020-A00256-33</secondary_id>
    <nct_id>NCT04262921</nct_id>
  </id_info>
  <brief_title>Clinical Characterisation Protocol for Severe Emerging Infections</brief_title>
  <acronym>CCP-nCoV</acronym>
  <official_title>Clinical Characterisation Protocol for Severe Emerging Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infectious disease is the single biggest cause of death worldwide. New infectious agents,
      such as the SARS, MERS and other novel coronavirus, novel influenza viruses, viruses causing
      viral haemorrhagic fever (e.g. Ebola), and viruses that affect the central nervous system
      (CNS) such as TBEV &amp; Nipah require investigation to understand pathogen biology and
      pathogenesis in the host. Even for known infections, resistance to antimicrobial therapies is
      widespread, and treatments to control potentially deleterious host responses are lacking.

      In order to develop a mechanistic understanding of disease processes, such that risk factors
      for severe illness can be identified and treatments can be developed, it is necessary to
      understand pathogen characteristics associated with virulence, the replication dynamics and
      in-host evolution of the pathogen, the dynamics of the host response, the pharmacology of
      antimicrobial or host-directed therapies, the transmission dynamics, and factors underlying
      individual susceptibility.

      The work proposed here may require sampling that will not immediately benefit the
      participants. It may also require analysis of the host genome, which may reveal other
      information about disease susceptibility or other aspects of health status.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2020</start_date>
  <completion_date type="Anticipated">August 7, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical features</measure>
    <time_frame>6 months</time_frame>
    <description>Describe the clinical features of the illness or syndrome (cardio-respiratory signs or symptoms, and laboratory results) and complications, and determinants of severity.
Assessment daily for 15 days, then weekly until max 100 days, then 3 and 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response to treatment</measure>
    <time_frame>6 months</time_frame>
    <description>Describe the response to treatments (including supportive care and novel therapeutics) by clinical, biological, radiological and virological assessments.
Assessment daily for 15 days, then weekly until max 100 days, then 3 and 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathogen replication, excretion and evolution, within the host</measure>
    <time_frame>6 months</time_frame>
    <description>high-throughput sequencing of pathogen genomes obtained from respiratory tract, blood, urine, stool, CSF and other samples.
Assessment on Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11, Day 13, Day 15 then weekly until max 100 days, then 3 and 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Immune host responses to infection and therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Characterise the innate and acquired immune responses, circulating levels of immune signalling molecules and gene expression profiling in peripheral blood.
Assessment on Day 1, Day 2, Day 3, Day 5, Day 7, Day 9, Day 11, Day 13, Day 15 then weekly until max 100 days, then 3 and 6 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Host genetic variants</measure>
    <time_frame>Day 1</time_frame>
    <description>Identify host genetic variants associated with disease progression or severity</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Coronavirus Infections</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, urine, stool /rectal swab, respiratory samples (nose and throat swab, endotracheal
      aspirate, nasopharyngeal aspirate), samples from infected sites/sores, CSF
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study will enrol eligible patients (children and adults) with confirmed or suspected
        infection with a pathogen relevant to the study objectives. Recruitment of patients with
        Day 1 (enrolment) data is the priority. The local study team will dictate whether
        laboratory confirmation of infection is required prior to enrolment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Suspected or proven novel Coronavirus (nCoV) infection as main reason for admission to
        hospital.

        Non inclusion criteria:

        - Subject deprived of freedom, subject under a legal protective measure

        Exclusion Criteria:

          -  Confirmed diagnosis of a pathogen unrelated to the objectives of this study and no
             indication or likelihood of co-infection with a relevant pathogen.

          -  Refusal by participant, parent or appropriate representative.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazdan YAZDANPANAH</last_name>
    <role>Study Chair</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yazdan YAZDANPANAH</last_name>
    <phone>+33 1 44 23 60 08</phone>
    <email>yazdan.yazdanpanah@inserm.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène ESPEROU</last_name>
    <phone>+33 1 44 23 60 70</phone>
    <email>helene.esperou@inserm.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Pellegrin, service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis MALVY</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP La Pitié Salpêtrière, service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric CAUMES</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Bichat, Service de réanimation médicale et infectieuse</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Francois TIMSIT</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP Bichat, Service des Maladies Infectieuses et Tropicales</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yazdan YAZDANPANAH</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 6, 2020</study_first_submitted>
  <study_first_submitted_qc>February 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2020</study_first_posted>
  <last_update_submitted>February 7, 2020</last_update_submitted>
  <last_update_submitted_qc>February 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronavirus</keyword>
  <keyword>2019-nCoV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

